2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine | 1105058-57-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine
• 英文别名: 2-(2,3-Difluoro-phenyl)-5H-1-imidazo[4,5-d]pyridazine；2-(2,3-difluorophenyl)-5H-1-imidazo[4,5-d]pyridazine；2-(2,3-difluoro-phenyl)-5H-imidazo[4,5-d]pyridazine
• CAS: 1105058-57-8
• 化学式: C₁₁H₆F₂N₄
• 分子量: 232.192
• InChiKey: RMQKBAIJLURYMC-UHFFFAOYSA-N

物化性质

• 沸点：
  369.8±52.0 °C(Predicted)
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.25
• 重原子数：
  17.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.46
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine 在 potassium carbonate 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 3-hydroxypropyl 2-(2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl)-2-(3-(4-propoxy-2-(trifluoromethyl)phenyl)isoxazol-5-yl)acetate
  参考文献：
  名称：

  Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism

  摘要：

  By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.

  DOI：

  10.1021/jm401337x
• 作为产物：
  描述：

  2,3-二氟苯甲酰氯 在 吡啶 、 tetraphosphorus decasulfide 、 三氯化硼 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazine
  参考文献：
  名称：

  Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure–Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism

  摘要：

  By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During this exploration, a facile decarboxylation was noted and was exploited as a novel prodnig mechanism. The synthesis and characterization of these prodrugs and their utilization in chronic toxicity studies are presented.

  DOI：

  10.1021/jm401337x

文献信息

• ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  申请人：Leivers Martin Robert

  公开号：US20090226398A1

  公开（公告）日：2009-09-10

  Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.

  披露了公式(I)的化合物和组合物、药物可接受的盐和溶剂化物，以及它们的制备和使用，用于治疗至少部分由黄病毒科病毒家族中的病毒介导的病毒感染。
• Imidazopyridazine Compounds for Treating Viral Infections
  申请人：Leivers Martin

  公开号：US20110052534A1

  公开（公告）日：2011-03-03

  Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses:

  揭示了化合物和Formula (I)的组成，其药用可接受的盐和溶剂，以及它们的制备和用于治疗至少部分由黄病毒科病毒介导的病毒感染的用途。
• Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
  申请人：Leivers Martin Robert

  公开号：US20100029655A1

  公开（公告）日：2010-02-04

  Disclosed are processes for the preparation of compounds of formula I and compositions that comprise said compounds of formula I. Also disclosed are processes for the preparation of compounds of formula III and compositions that comprise said compounds of formula III.

  公开了制备公式I化合物的过程以及包含所述公式I化合物的组合物。 还公开了制备公式III化合物的过程以及包含所述公式III化合物的组合物。
• [EN] ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS ANTIVIRAUX, COMPOSITIONS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENELABS TECH INC

  公开号：WO2009011787A1

  公开（公告）日：2009-01-22

  Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses. (I)

  揭示了式（I）的化合物，其药用盐和溶剂化合物，以及其组合物，以及其制备方法和用于治疗至少部分由黄病毒科病毒介导的病毒感染的用途。
• [EN] ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS ANTIVIRAUX, COMPOSITIONS ET MÉTHODES D'APPLICATION
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010081149A1

  公开（公告）日：2010-07-15

  Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.

  揭示了式（I）的化合物，其药用可接受的盐，以及它们的组合物，制备方法和用于治疗至少部分由黄病毒科病毒介导的病毒感染的用途。